A single dose of Rebinyn® 40 IU/kg was shown to elevate factor levels above their normal levels in pediatric patients.d Take a look at the numbers:
TAKE CONTROL WITH HIGH FACTOR LEVELS
Rebinyn® is proven to achieve and maintain higher factor levels.a
HIGH FACTOR ACTIVITY IN CHILDREN AND ADOLESCENTS
dBased on pharmacokinetic assessment of a single dose of Rebinyn® 40 IU/kg after 7 days in 3 adolescents (mean FIX activity 14.6%), 13 children aged 7 to 12 (mean FIX activity 10.9%), and 12 children aged 0-6 (mean FIX activity 8.4%) upon enrollment in the phase 3 trials using 1-stage assay and product-specific standard. All values are geometric mean.
eBased upon a 1.51% increase in factor levels per IU/kg infused in children aged ≤6.
fBased upon a 1.59% increase in factor levels per IU/kg infused in children aged 7-12.
gBased upon a 1.96% increase in factor levels per IU/kg infused in adolescents aged 13-17.
INTERESTED IN TRYING REBINYN®?
To learn more about our free trial prescription program, please callto speak with a NovoSecure™ Specialist.h
hPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.